文献速递造血干细胞移植与细胞治疗

同伴支持干预在接受造血干细胞移植患者中的初步随机临床试验

A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation.
PubMed 文献 · Blood Adv · 2026-01-01

本研究评估STEPP同伴支持干预(由HSCT幸存者通过电话提供5次心理教育和应对策略)的可行性、可接受性及初步效果。77%的合格患者入组,STEPP组全部完成至少3次 sessions,CSQ均分3.5,超过可行性阈值。STEPP在焦虑、抑郁、创伤后应激、生活质量、社会支持和自我效能方面显示出小到中等改善,值得开展多中心确证性试验。

要点

  • STEPP干预可行且可接受:入组率77%,全部完成至少3次,CSQ均分3.5。
  • 初步显示焦虑(d=-0.36至-0.58)、抑郁(d=-0.25)等心理社会结局改善。
  • 需开展多中心、充分把握度的确证性试验验证疗效。

核心结论

  • STEPP同伴支持干预超过可行性和可接受性阈值,并显示出有前景的心理社会获益。

研究设计与样本

  • 初步随机临床试验,招募HSCT前1-2周的患者,随机分配至STEPP组或常规护理组。
  • STEPP为5次电话干预,由HSCT幸存者提供心理教育和应对策略。
  • 共入组90例(STEPP组45例,常规护理组45例),其中78例为活跃参与者(平均年龄58.9岁,标准差12.3;57.7%女性)。

主要发现

  • 入组率为77%(90/117),STEPP组所有参与者完成至少3次干预,CSQ平均分3.5。
  • 第30天焦虑效应量d=-0.36,第60天焦虑d=-0.58、抑郁d=-0.25、创伤后应激d=-0.28。
  • 第60天生活质量d=0.48、社会支持d=0.36、自我效能d=0.46。

关键数值与推荐

  • 可行性定义为入组率≥60%且≥60%完成至少3次干预。
  • 可接受性采用CSQ评估,均值≥3/4为基准。
  • 主要结局指标包括焦虑、抑郁(HADS)、创伤后应激(PCL-C)、QOL(FACT-BMT)、社会支持(SSEQ)和自我效能(CSES),在HSCT前及移植后30天和60天评估。

临床怎么用

  • STEPP可作为可扩展的同伴支持干预,用于减轻HSCT患者心理困扰并改善生活质量。
  • 由HSCT幸存者通过电话提供结构化心理教育和应对策略,可行性良好。

局限性

  • 为初步试验,样本量有限,需 fully powered 多中心确证性试验验证疗效。
  • 12例因HSCT取消或推迟而变得不合格。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peer support has been associated with improved patient-reported outcomes (PROs), including reduced psychological distress, among patients undergoing hematopoietic stem cell transplantation (HSCT), but structured interventions are limited. This study assessed the feasibility, acceptability, and preliminary effects of a scalable peer support intervention to reduce psychological distress and enhance quality of life (QOL) post-HSCT. We conducted a pilot randomized clinical trial evaluating the Supporting Transplant Experiences with Peer Program (STEPP), a 5-session, telephone-based intervention delivered by an HSCT survivor offering psychoeducation and coping strategies. Participants were recruited 1 to 2 weeks pre-HSCT admission and randomized to STEPP or usual care. Feasibility was defined as ≥60% enrollment and ≥60% completing ≥3 sessions. Acceptability was assessed using the Client Satisfaction Questionnaire (CSQ; ≥3/4 mean benchmark). PRO measures of anxiety, depression (Hospital Anxiety and Depression Scale), posttraumatic stress (Post-Traumatic Stress Disorder Checklist-Civilian Version), QOL (Functional Assessment of Cancer Therapy-Bone Marrow Transplant), social support (Social Support and Effectiveness Questionnaire), and self-efficacy (Cancer Self-Efficacy Scale) were assessed pre-HSCT and at 30 and 60 days post-HSCT. Mixed-effects models explored preliminary effects. We enrolled 77% (90 of 117) of eligible patients (STEPP, n = 45; usual care, n = 45); 12 became ineligible due to HSCT cancellation or postponement. Among 78 active participants (mean age, 58.9 years [standard deviation, 12.3]; 57.7% women), all STEPP participants completed ≥3 sessions, and the mean CSQ score was 3.5. STEPP showed small-to-moderate improvements in day 30 anxiety (d = -0.36) and day 60 anxiety (d = -0.58), depression (d = -0.25), posttraumatic stress (d = -0.28), QOL (d = 0.48), social support (d = 0.36), and self-efficacy (d = 0.46). STEPP exceeds feasibility and acceptability thresholds, showing promising psychosocial benefits warranting a fully powered multisite efficacy trial. This trial was registered at www.clinicaltrials.gov as NCT06010017.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Amonoo HL, Keane EP, Guo M, et al. A pilot randomized clinical trial of a peer support intervention for hematopoietic stem cell transplantation. Blood Adv. 2026. PMID: 41945755. doi:10.1182/bloodadvances.2025018918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。